Table 6. Summary of association results of included studies.
| Association result | Gleason (n=28)* | Stage (n=18) | PSA (n=18)* | |||
|---|---|---|---|---|---|---|
| P<0.05 | Pos | T | Arisan, 2020; Guan, 2016; Li, 2012; Melbø-Jørgensen, 2014; Zhao, 2019a | Li, 2012; Melbø-Jørgensen, 2014; Reis, 2012; Zhao, 2019a | ||
| C | Al-Qatati, 2017; Gurbuz, 2020; Ibrahim, 2019a; Ibrahim, 2019b; Ju, 2019; Yang, 2016 | Al-Qatati, 2017; Gurbuz, 2020; Huang, 2015b; Ibrahim, 2019a; Ibrahim, 2019b; Ju, 2019; Stuopelyte, 2016; Yang, 2016 | Al-Qatati, 2017; Gurbuz, 2020; Ibrahim, 2019b | |||
| U | Samaan, 2014 | |||||
| Neg | T | Ren, 2014 | Ren, 2014 | |||
| P >0.05 | Pos | T | Katz, 2014; Kurul, 2019; Lichner, 2015; Reis, 2012; Zedan, 2017; Zedan, 2018 | Zedan, 2017 | Li, 2012; Reis, 2012; Zedan, 2018; Zhao, 2019a | |
| C | Shen, 2012 | Shen, 2012 Zedan, 2019 |
Ju, 2019; Shen, 2012; Zedan, 2018; Zedan, 2019 | |||
| Neg | T | Kristensen, 2016** | Katz, 2014 | Zedan, 2017 | ||
| C | Kotb, 2014; Zedan, 2018; Zedan, 2019 | Sharova, 2021; Yang, 2016; Zhao, 2019b | ||||
| No diff | T | Amankwah, 2013 | Guan, 2016; Katz, 2014 | |||
| C | Farran, 2018; Foj, 2017; Stuopelyte, 2016 | |||||
|
No
P-value |
Pos | T | Hart, 2014 | |||
| No corr | C | Agaoglu, 2011 | ||||
| Association result | Recurrence (n=19) | Metastasis (n=14) | Risk (n=12) | Age (n=9) | ||
|---|---|---|---|---|---|---|
| P<0.05 | Pos | T | Leite, 2015; Li, 2012; Melbø-Jørgensen, 2014; Reis, 2012 | Guan, 2016; Li, 2012 | Zhu, 2019 | |
| C | Huang, 2015b; Ju, 2019; Yang, 2016 | Agaoglu, 2011; Brase, 2011; Huang, 2015b; Ibrahim, 2019a; Ibrahim, 2019b; Watahiki, 2013; Yang, 2016; Ju, 2019 | Foj, 2017; Ju, 2019; Shen, 2012 | Zedan, 2019 | ||
| Neg | T | Suer, 2019**; Amankwah, 2013 | Ren, 2014 | Ren, 2014 | ||
| C | Danarto, 2020 | |||||
| P>0.05 | Pos | T | Kurul, 2019; Leite, 2011; Ren, 2014 | Katz, 2014; Leite, 2013; Zedan, 2017 | ||
| C | Stuopelyte, 2016 | Al-Qatati, 2017; Hoey, 2019; Sapre, 2014; Zedan, 2019 | Huang, 2015b; Yang, 2016 | |||
| Neg | T | Katz, 2014 | Leite, 2011 | Lichner, 2013 | Zhao, 2019a; Li, 2012 | |
| C | Selth, 2013; Shen, 2012 | Shen, 2012; Zhao, 2019b | ||||
| No diff/corr | T | Kristensen, 2016**; Zheng, 2014 | Guan, 2016 | |||
| C | Singh, 2014 | |||||
|
No
P-value |
Pos | T | Bonci, 2016 | |||
Most of the 64 studies included in this review compared the association of miR-21 with commonly used clinicopathological prognostic factors (Gleason score/grade; pathological/clinical stage; serum PSA level; risk stratification; age at diagnosis), as well as recurrence and metastasis.
Study IDs in bold were eligible for meta-analysis (n=11).
Abbreviations: C, circulating miR-21; corr, correlation; diff, difference; Neg, negative association; Pos, positive association; PSA, prostate-specific antigen; T, tissue miR-21; U, unknown miR-21 source
*
Zedan, 2018 [86] was counted twice as both tissue and plasma miR-21 expressions were measured.
**
3p strand of miR-21 was measured.